Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 2/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12431478 | 0.93 | HPGD (0.49) | ALDH1A1HPGDSMN1; SMN2MLYCDPLK1 | |
| SCHEMBL21077862 | 0.87 | MLYCD (0.62) | ALDH1A1HPGDSMN1; SMN2MLYCDPLK1 | |
| SCHEMBL7157289 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HPGDMLYCDEGFRERBB2 | |
| SCHEMBL11919822 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDSMN1; SMN2MLYCDPLK1 | |
| SCHEMBL10076226 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDSMN1; SMN2MLYCDPLK1 | |
| SCHEMBL3559829 | 0.82 | HPGD (0.61) | ALDH1A1HPGDSMN1; SMN2MLYCDPLK1 | |
| SCHEMBL22851740 | 0.82 | HPGD (0.44) | ALDH1A1HPGDSMN1; SMN2MLYCDPLK1 | |
| SCHEMBL19634427 | 0.81 | HDAC3 (0.48) | ALDH1A1MLYCDEGFRERBB2HDAC1 | |
| SCHEMBL7456186 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2MLYCDEGFR | |
| SCHEMBL12194867 | 0.81 | MLYCD (0.58) | ALDH1A1HPGDSMN1; SMN2MLYCDPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-7879863-B2 | Kallikrein inhibitors such as N-((2R)-3-methyl-2-{[4-(trifluoromethyl)phenyl]amino}butyl)-2-phenylacetamide trifluoroacetate, used for the treatment of gastrointestinal disorders, periodontal diseases, skin disorders, arthritis, hypotension, edema, respiratory system disorders and proliferative diseases | AJINOMOTO CO., INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | ALDH1A1 747/4885HPGD 735/4885SMN1; SMN2 4457/4885 |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | ALDH1A1 4455/4885HPGD 4123/4885SMN1; SMN2 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.